Autolus Therapeutics Ltd (NYSE:AUTL) Q1 2020 Earnings Conference Call - Final Transcript
May 07, 2020 • 08:30 am ET
Ladies and gentlemen, thank you for standing by, and welcome to the Autolus Therapeutics First Quarter 2020 Financial Results and Operation Highlights Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. [Operator Instructions]
I would now like to hand your conference over to your speaker today, Mr. -- excuse me, Dr. Lucinda Crabtree, Vice President of Investor Relations. Thank you. Please go ahead, ma'am.
Thank you, Kara. Good morning, and/or good afternoon, everyone, and thank you for taking part in today's call on the financial results and operational highlights for the first quarter 2020. I am Lucinda Crabtree, Vice President of Investor Relations. With me today are Dr. Christian Itin, our Chairman and Chief Executive Officer; and Andrew Oakley, our Chief Financial Officer.
Before we begin, I would like to remind you that during this call, we will be making forward-looking statements. All statements other than statements of historical facts contained in this forward-looking statements. Our actual results, performance or achievements may be materially different from those expressed or implied by the forward-looking statements. For a discussion of the risks and uncertainties relating to our business and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, please see the section titled Risk Factors in our annual report on Form 20-F filed on March 3, 2020 as well as discussions of potential risks, uncertainties and other important factors in our other periodic filings with the SEC.
The forward-looking statements contained in this presentation reflect the company's views as of the date of this presentation regarding future events. And the company does not assume any obligation to update any forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing the company's views as of any date subsequent to the date of this presentation.
So with that, on Slide 3, you'll see the agenda for today, and it is as follows: Christian will provide a brief introduction, and that will be followed by our operational highlights for the first quarter of 2020. Andrew will next discuss the company's financial results, and then Christian will conclude with upcoming milestones and other concluding comments. And of course, we welcome your questions following our remarks.
So with that, I'd like to now turn the call over to Christian. Thank you.
Christian Martin Itin
Thank you, Lucinda, and welcome to all of you, and thank you for joining us. I'm pleased to review our progress for the first quarter in 2020. Firstly, on Slide 5, we are pleased to report on a very productive first quarter. We remain on track with our clinical programs, despite the challenges of COVID-19. As an organization, we have quickly adapted to this challenging environment, ensuring business continuity. Our focus has been on ensuring our clinical B-cell programs, AUTO1 and AUTO3, continue to progress, and we remain on track with recruitment ongoing and manufacturing operations uninterrupted. As such, we expect to deliver data in the time lines that